Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IRS2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IRS2 Recombinant Protein (Full-length & PTB Domain). High purity (>95%), E.coli/HEK293 expressed, Sequence Verified. Endotoxin <1EU/ug. | View IRS2 Products |
| Gene Delivery | IRS2 Lentivirus Premade Particles / Promise-ORF. Full-length ORF for stable cell line construction. Sequence Verified, Puromycin selection. | View IRS2 Products |
| Benchmark Ab | Anti-IRS2 Rabbit Monoclonal / Recombinant Antibody. Sequence Verified, suitable for Western, IP, ELISA. | View IRS2 Products |
| Validator | IRS2 siRNA Set (3 unique targets). For knockdown verification and specificity controls. | View IRS2 Products |
| Counter-Screen | IRS1 Recombinant Protein. Paralog protein for selectivity screening (70% homology). | View IRS1 Products |
| Upstream Kinase | INSR (Insulin Receptor) ECD-Fc / Kinase Domain. For phosphorylation-dependent binding assays. | View INSR Products |
| Alternative Pathway | IGF1R (Insulin-like Growth Factor 1 Receptor). Alternative upstream activator of IRS2. | View IGF1R Products |
| Downstream Effector | PIK3CA. Downstream effector in the oncogenic/metabolic signaling pathway. | View PIK3CA Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Signaling Studies | IRS2 Lentivirus for stable cell line construction (HEK293/HeLa). Sequence Verified, Puromycin selection. |
| IRS1/IRS2 Selectivity Screening | Matched pair: Human IRS2 & IRS1 recombinant proteins (>95% purity, verified by Mass Spec). |
| Phosphorylation Site Mapping | IRS2 PTB domain protein (pY-binding) for phospho-peptide pulldown assays. |
| PPI Validation (Protein-Protein Interaction) | Full-length IRS2 with intact YXXM motifs. High purity for AlphaScreen/SPR. |
| Scaffolding Protein Binding (PPI Disruption) | Full-length and domain-specific recombinant proteins available with >95% purity for SPR/BLI. |
| PROTAC Degradation Assays | HEK293 Expressed (Native Post-Translational Modifications) to ensure relevant ubiquitination mapping. |
| Lack of Controls | High-affinity recombinant antibodies included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks and functional baseline setup. |
Live IRS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
Because IRS2 is a large intracellular scaffolding protein lacking intrinsic enzymatic activity, traditional small molecule inhibitors have struggled. The race for IRS2-targeted therapeutics is intensifying, with major players shifting focus from conventional upstream receptor inhibition (IGF1R/INSR) to direct adaptor protein targeting via Targeted Protein Degradation (TPD)—such as PROTACs and molecular glues—and Allosteric PPI Inhibitors. As first-generation metabolic disease therapies face resistance limitations, the next wave of R&D is targeting IRS2-mediated compensatory signaling mechanisms, including selective degradation to combat IGF1R/INSR-driven malignancies and insulin resistance bypass mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC Degraders | Academic Consortia, Preclinical Biotech | Solid Tumors (Breast, Prostate), Metabolic Disorders | Degradation Assay (Need High-Purity Native Protein for ternary complex modeling); Pull-down Assay |
| Small Molecule PPI | Pharma Research, Academic / Early Pharma | Type 2 Diabetes, Metabolic Disorders | PTB Domain Binding Assay (IRS2 PTB vs Phospho-peptide); Binding Affinity (Domain-specific proteins) |
| Bi-functional Inhibitors | Emerging Biotech | Insulin Resistance | Dual IRS1/IRS2 Selectivity Panel (Ortholog proteins) |
| Peptide Inhibitors | Academic Labs | Metabolic Syndrome | Cell Penetration Assay (IRS2 Lentivirus stable line) |
| siRNA / ASO | RNAi developers | Hepatic steatosis / Cancer | Knockdown Validation (Sequence Verified siRNA and benchmark Abs) |